{"id":540044,"date":"2021-04-22T17:58:01","date_gmt":"2021-04-22T17:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=540044"},"modified":"2021-04-22T17:58:01","modified_gmt":"2021-04-22T17:58:01","slug":"melas-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-cyclerion-therapeutics-inc-khondrion-bv-abliva-aband-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/melas-syndrome-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-cyclerion-therapeutics-inc-khondrion-bv-abliva-aband-others_540044.html","title":{"rendered":"MELAS Syndrome Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Cyclerion Therapeutics Inc., Khondrion BV, Abliva ABand Others."},"content":{"rendered":"
\"MELAS<\/a><\/p>\n
\n
MELAS Syndrome Pipeline<\/div>\n<\/div>\n<\/div>\n

MELAS syndrome<\/strong> (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes syndrome) is a rare disorder that begins in childhood, usually between two and fifteen years of age, and mostly affects the nervous system and muscles. The most common early symptoms are seizures, recurrent headaches, loss of appetite and recurrent vomiting. Symptoms of MELAS syndrome usually begin between the ages of two and fifteen years, but delayed onset cases have also been reported between fifteen and forty years and late onset cases after forty years. MELAS is caused by mutations in mitochondrial DNA. Some cases of MELAS syndrome appear to occur as the result of a new spontaneous mutation in a mitochondrial gene and are not inherited. It affects males and females in equal numbers.<\/p>\n

DelveInsight’s, “MELAS Syndrome Pipeline<\/a> Insight, 2021,”<\/strong> report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in MELAS Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. <\/p>\n

 <\/p>\n

Some of MELAS Syndrome Companies are:<\/strong><\/p>\n